Document is current
Any future updates will be listed below
-
Authors
Skiba, Meredith A.
Sterling, Sarah M.
Rawson, Shaun https://orcid.org/0000-0002-2973-2630
Zhang, Shuhao https://orcid.org/0000-0002-0301-5983
Xu, Huixin
Jiang, Haoran https://orcid.org/0000-0001-5916-3072
Nemeth, Genevieve R.
Gilman, Morgan S. A.
Hurley, Joseph D. https://orcid.org/0000-0002-3903-318X
Shen, Pengxiang https://orcid.org/0000-0002-6941-4741
Staus, Dean P.
Kim, Jihee
McMahon, Conor
Lehtinen, Maria K.
Rockman, Howard A. https://orcid.org/0000-0003-2921-1584
Barth, Patrick https://orcid.org/0000-0002-0744-6844
Wingler, Laura M. https://orcid.org/0000-0002-3688-5088
Kruse, Andrew C. https://orcid.org/0000-0002-1467-1222
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R21HD101596, R01CA260415, K99HD110612)
Helen Hay Whitney Foundation
Howard Hughes Medical Institute
New York Stem Cell Foundation
Pew Charitable Trusts
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A_182263, 310030_208179)
Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 17 July 2023
Accepted: 12 April 2024
First Online: 14 May 2024
Competing interests
: A.C.K., C.M., L.M.W., D.P.S. and M.A.S. are co-inventors on a patent application for AT1R blocking nanobodies. A.C.K. is a cofounder and consultant for biotechnology companies Tectonic Therapeutic and Seismic Therapeutic, and also for the Institute for Protein Innovation, a nonprofit research institute. L.M.W. is a scientific advisor for Septerna. D.P.S. is a Septerna employee. C.M. is a Sanofi employee. P.B. holds patents and provisional patent applications in the field of engineered T-cell therapies and protein design. The other authors declare no competing interests.
